# Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

> **NCT01189903** · PHASE2,PHASE3 · UNKNOWN · sponsor: **National University Hospital, Singapore**

## Conditions studied

- Asian Colorectal Cancer Patients

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT01189903
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2013-08
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189903, "Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01189903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*